December 5 – 6, 2022 | Washington, DC, USA & LIVE Streamed

A Multi-stakeholder Multi-specialty
NASH Trialists Think Tank

Metabolic, hepatology, nephrology & cardiovascular cross talk

French Embassy, Reservoir Road, Washington, DC, USA and LIVE Streamed

A Multi-stakeholder
Multi-specialty
NASH Trialists Think Tank

Metabolic, hepatology, nephrology & cardiovascular cross talk

Overview
MOSAIC - the 1st Global NASH Trialist Forum
will bring together cardiology, endocrinology & hepatology clinical trialists, industry, regulatory experts, payers, patients representatives and other stakeholders to further advance collective intelligence and foster collaboration about NASH diagnosis and management.
MOSAIC - the 1st Global NASH Trialist Forum
will bring together cardiology, endocrinology & hepatology clinical trialists, industry, regulatory experts, payers, patients representatives and other stakeholders to further advance collective intelligence and foster collaboration about NASH diagnosis and management.
NASH: a major unmet need in clinical trial science
it is now clear that non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are a public health problem worldwide.
• It affects around 25-30% of the adult population and causes considerable liver-related and extra-hepatic morbidity and mortality.
• NASH is considered a metabolic and multi organ disease with cardiovascular complications, worsening metabolic dysfunction and other extra-hepatic diseases, such as type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), or certain extra-hepatic cancers.
Learning Objectives
Why you should attend?
  • list icon
    Networking opportunities
  • list icon
    Think Tank focused Workshops
  • list icon
    Latest trials updates
  • list icon
    Patient participation
Chairs
Stephen Harrison
USA
Veronica Miller
USA
Arun Sanyal
USA
chair-eclipse
Faiez Zannad
France
Topics
  • NASH – Cardiovascular Intersections
  • Epidemiology, disease mechanisms
  • NonInvasive Tests (NITs)
  • Trial design issues and innovations
  • Patient population selection in NASH trials
  • Endpoints
  • Pathways to approval
  • Therapeutics
  • Experiences and case studies
Topics